Sachdev Sidhu is a Research Professor and Entrepreneur in Residence at the University of Waterloo. His research focuses on synthetic antibodies, protein engineering, and biotechnological applications. He leads efforts in developing novel therapeutic antibodies, engineered protein systems, and molecular tools for biomedical research. His work spans cancer therapy, viral infection countermeasures, and regenerative medicine. Sidhu is also involved in translational research, bridging academic discoveries with commercial applications through entrepreneurial ventures. Key research interests include synthetic antibody libraries, CAR T-cell engineering, ubiquitin-based therapeutics, and phage display technologies. He has contributed to advancements in targeted therapies for glioblastoma, leukemia, and ocular diseases. His team develops innovative methods for protein design, such as engineered ubiquitin variants and modular antibody architectures. Publications highlight breakthroughs in antibody-based treatments, including synNotch CAR T cells for glioblastoma and neutralizing antibodies against SARS-CoV-2. His work integrates structural biology, molecular biology, and computational approaches to address complex biomedical challenges. Sidhu collaborates with industry partners to advance technologies into clinical and commercial settings.
Professor Guy Williams is a leading academic at the University of Cambridge with a focus on imaging science and clinical neurosciences, affiliated with Downing College and the Wolfson Brain Imaging Centre . Holding a PhD in Physics from his initial Natural Sciences degree, he specializes in nuclear magnetic resonance (NMR) and MRI techniques for brain imaging. Education: BA, PhD in Physics His research centers on non-invasive imaging of brain structure and function, particularly in traumatic brain injury (TBI) and dementia. His work involves developing novel MRI pulse sequences and advanced data analysis algorithms, including AI-based diagnostic tools. He leads studies on white matter integrity post-trauma, longitudinal dementia assessment, and applications of MRI in disorders of consciousness and addiction. Recent publications highlight collaborations in traumatic brain injury outcomes, AI-guided dementia prediction, and neuroimaging of post-COVID cognitive deficits. His team's work on ultra-high field laminar fMRI and distortion correction methods has advanced clinical neuroscience applications. Key techniques include diffusion tensor imaging (DTI), 7 Tesla MRI, and positron emission tomography (PET/MR). His research spans from basic NMR physics to clinical translation, with a strong emphasis on multi-site studies and real-world diagnostic implementation.
Dr. Michael Baym is an Associate Professor of Biomedical Informatics at Harvard Medical School with affiliate appointments in Microbiology and the Laboratory of Systems Pharmacology, and as an Associate Member of the Broad Institute. He leads the Baym Lab, which studies microbial evolutionary genomics and antibiotic resistance through a hybrid of experimental, computational, and theoretical approaches. His research focuses on: Antibiotic Resistance Evolution and practical interventions Mobile Genetic Elements (plasmids, phages, transposons) Computational Genomic Algorithms for big data analysis Synthetic Biology tools and technologies Key recent publications explore phage discovery systems , phylogenetic compression of microbial genomes, and RNA-guided gene drives in plasmids. His work is supported by multiple NIH/NIGMS and NSF grants including a MIRA award. Scientific honors include: Packard Fellowship (2018) Pew Biomedical Scholarship (2020) Sloan Research Fellowship (2020) A. Clifford Barger Excellence in Mentoring Award (2021) SSQBio Mentorship Award (2022) The lab actively trains PhD students and postdoctoral fellows with alumni occupying academic and industry positions globally. Current team members include researchers from interdisciplinary backgrounds working at the intersection of experiment, computation, and theory .
Jeffrey Beekman is a Full Professor at the University Medical Center Utrecht, specializing in translational research for chronic diseases through the Department of Pediatric Pulmonology. His work bridges basic and clinical research to develop novel diagnostics and therapeutics for conditions like cystic fibrosis (CF) and Primary Ciliary Dyskinesia. Education: PhD in Molecular Immunology (2004) Key Roles: Principle Investigator since 2010, co-founder of FAIR Therapeutics, Board Member of the Dutch Society for Stem Cell Research His research focuses on patient-derived organoid models to study disease mechanisms, validate therapeutic targets, and optimize drug development. Strategic programs include Child Health and Regenerative Medicine & Stem Cells . Recent publications highlight his work on CFTR gene therapy, organoid-based drug efficacy testing, and host-pathogen interactions in CF. Collaborations span molecular biology, clinical pulmonology, and biotech translation. Key Techniques: Organoid modeling, RNA sequencing, Forskolin-induced swelling assay Diseases Studied: Cystic Fibrosis, Colorectal Cancer Susceptibility, Primary Ciliary Dyskinesia
University of California, Los AngelesUnited States
Jeff S Abramson is a Professor of Physiology in the David Geffen School of Medicine at the University of California Los Angeles (UCLA). His research focuses on the structural and functional characterization of membrane transport proteins, particularly sugar transporters and mitochondrial channels. He maintains an active laboratory investigating the molecular mechanisms of cellular transport processes. Dr. Abramson's primary research interests center on membrane transport proteins, with particular emphasis on sugar symporters and voltage-dependent anion channels (VDACs). His work combines structural biology, biophysics, and biochemistry to understand the molecular mechanisms of transport, including conformational changes during transport cycles, substrate recognition, and regulation by membrane potential. His research has significant implications for understanding metabolic disorders, mitochondrial function, and potential therapeutic targets. Analysis of Dr. Abramson's publication record reveals a consistent focus on membrane protein structure-function relationships over the past two decades. His work demonstrates expertise in X-ray crystallography, cryo-electron microscopy, and functional assays to characterize transport proteins. Recent publications show increasing emphasis on mitochondrial biology, particularly VDAC structure and function, while maintaining his longstanding interest in sugar transport mechanisms. His research bridges fundamental biophysical principles with potential biomedical applications in metabolic diseases. Dr. Abramson has been awarded multiple NIH grants supporting his research, including the R35GM135175 grant titled 'Deciphering molecular details of cellular sugar transport and their roles in disease' (2020-2024), R01GM124783 'Functional and structural studies of unique pathogenic transporters involved in glycobiology' (2017-2021), and R01GM078844 'Structural and functional characterization of sugar transporters in health and disease' (2006-2020). As Principal Investigator, Dr. Abramson has mentored numerous graduate students and postdoctoral researchers. His laboratory has made significant contributions to understanding the structure-function relationships of membrane transport proteins through collaborations with researchers across multiple disciplines. The lab utilizes advanced techniques including X-ray crystallography, cryo-EM, electrophysiology, and computational modeling to address fundamental questions about membrane protein mechanisms. Dr. Abramson's laboratory is part of UCLA's broader research ecosystem focused on structural biology and membrane protein research. His work intersects with several research centers at UCLA including those focused on metabolic diseases and structural biology. The lab maintains active collaborations with researchers specializing in biophysics, computational modeling, and disease mechanisms to translate basic findings into potential biomedical applications.
Luca Varani is a Professor and Group Leader of the Structural Biology group at the Institute for Research in Biomedicine (IRB), affiliated with the Università della Svizzera italiana in Bellinzona, Switzerland. His research focuses on understanding the molecular mechanisms of antibody-pathogen interactions and engineering novel therapeutic antibodies. Education: Chemistry degree from University of Milan, PhD from MRC-Laboratory of Molecular Biology (University of Cambridge) Former postdoc at Stanford with EMBO fellowship Founder of CLBiotech (2022), a nanobody discovery and engineering startup Varani's research spans structural biology, immunology, and biophysics with emphasis on viral pathogenesis and antibody engineering. His work combines experimental and computational approaches to study antibody-antigen interactions, particularly against emerging pathogens like SARS-CoV-2, Zika, and Dengue viruses. His group has pioneered structure-guided antibody engineering techniques that have led to multiple high-impact publications in journals like Nature, Cell, and Science. Analysis of Varani's recent publications reveals a strong focus on SARS-CoV-2 antibody responses, with significant contributions to understanding neutralizing mechanisms, viral escape, and therapeutic antibody development. His work also extends to prion diseases, cancer immunology, and flaviviruses, demonstrating a multidisciplinary approach that bridges structural biology with translational medicine. As a reviewer for high-impact journals and international granting agencies, Varani contributes significantly to the scientific community. He also serves as an evaluator for European startup accelerator programs and consults for antibody biotechnology companies, translating academic research into practical applications. Varani leads a highly multidisciplinary research team that employs techniques ranging from NMR spectroscopy and X-ray crystallography to cellular assays and computational modeling. His laboratory has been instrumental in developing bispecific antibodies against SARS-CoV-2 and other pathogens, with several candidates advancing toward clinical trials.
Leibniz Institute for Zoo and Wildlife ResearchGermany
Dr. Andrew Bassett serves as Head of the Cellular and Gene Editing Research group at the Wellcome Sanger Institute, where he develops cutting-edge genome engineering techniques using human pluripotent stem cells to investigate neurodegenerative diseases including Alzheimer's and Parkinson's. His work focuses on scaling genetic screening approaches and improving CRISPR specificity for modeling complex disease mechanisms. His academic training includes: PhD at the MRC Laboratory of Molecular Biology (MRC-LMB) with Andrew Travers on chromatin remodelling in heterochromatin formation Postdoctoral research with David Baulcombe at the University of Cambridge studying small RNA roles in chromatin modification Additional postdoctoral work with Chris Ponting at the MRC Functional Genomics Unit (MRC-FGU) in Oxford, where he pioneered CRISPR applications in Drosophila Bassett's research program centers on developing advanced genome engineering methodologies for precise modulation of gene expression networks during development and neurodegeneration. His group specializes in creating complex editing events (SNPs, paired knockouts, enhancer perturbations) within iPSC-derived models, with particular emphasis on epigenetic regulation and transcriptional control. Current projects integrate single-cell 'omics and phenotypic assays to decode genetic causes of neurodegenerative disorders through the OpenTargets consortium. Analysis of his 15 most recent publications reveals dominant trends in CRISPR technology development (35%), neurodegenerative disease modeling (30%), and single-cell functional genomics (25%). His work consistently bridges methodological innovation with disease mechanism studies, increasingly incorporating multi-omics approaches and expanding into cancer immunology and infectious disease applications since 2022. As group leader, Bassett mentors postdoctoral researchers and PhD students while securing major funding for genome engineering initiatives. His team operates within the Sanger Institute's Cellular Operations division and maintains critical partnerships with the OpenTargets consortium for therapeutic target validation. The laboratory specializes in high-throughput screening platforms using iPSC-derived neural and microglial models, with recent methodological advances including scSNV-seq and ONE-STEP tagging systems that significantly enhance precision genome editing capabilities.
Professor Dario Alessi is a leading academic at the University of Dundee's School of Life Sciences, serving as the Director of the MRC Protein Phosphorylation Unit (MRC PPU) and Professor of Signal Transduction. He earned his BSc (1988) and PhD (1991) from the University of Birmingham. His research focuses on protein phosphorylation and ubiquitylation pathways, particularly the LRRK2 kinase pathway linked to Parkinson's disease. He has made groundbreaking contributions to understanding LRRK2's role in neurodegeneration, including its interaction with Rab proteins and scaffolding molecules like RILPL1. School of Life Sciences, University of Dundee MRC PPU Director since 2012 Signal Transduction Therapy Unit Director His work combines molecular biology, biochemistry, and collaborative industry partnerships to advance therapeutic strategies for Parkinson's disease. Key research areas include LRRK2 activation mechanisms, Rab protein phosphorylation, and lysosomal dysfunction. Alessi has trained over 30 graduate students and 40 postdocs, many now in academic and industry leadership roles. Notable awards include the EMBO Gold Medal (2005), the Robert A. Pritzker Prize for Leadership in Parkinson’s Research (2023), and an OBE (2023) for contributions to medical science. His lab promotes open science, sharing reagents and protocols globally through platforms like MRC Pure Agents and LRRK2.bio. Current projects include investigating novel mitochondrial and organelle biology in Parkinson’s, developing biomarkers, and advancing LRRK2 inhibitors through clinical trials. Collaborations span the Michael J. Fox Foundation, Aligning Science Across Parkinson’s, and the UK Dementia Research Initiative.
Doron Betel serves as an Assistant Professor at Weill Cornell Medicine's Graduate School of Medical Sciences, with affiliations in both the Physiology, Biophysics & Systems Biology and Computational Biology programs. He directs the Applied Bioinformatics Core (ABC), a central service group providing specialized computational and analytical support for biomedical research across multiple institutions. Dr. Betel's research focuses on developing computational genomic tools for studying human diseases and cellular development, with emphasis on integrative analyses of genomic and epigenomic data from high-throughput assays. His work addresses specific questions related to disease progression, treatment response, stem cell differentiation, and neurological processes through two closely interacting research groups: the Applied Bioinformatics Core and his independent research lab. The analysis of his recent publications reveals a strong emphasis on single-cell and spatial genomics, cross-species data integration, and machine learning applications in cancer immunology and neurodegenerative disease modeling. His research spans multiple high-impact areas including cancer immunotherapy, stem cell biology, diabetes research, and cardiovascular regeneration, with numerous publications in top journals like Nature, Cell, and Nature Immunology. Through the Applied Bioinformatics Core, Dr. Betel provides extensive analytical support across various genomic platforms including single-cell RNA-seq, spatial transcriptomics, ChIP-seq, ATAC-seq, and variant calling. The Core serves as a vital resource for researchers at Weill Cornell Medicine and the broader Tri-Institutional network, offering specialized analysis, computational pipelines, and training services. Dr. Betel maintains extensive collaborations with leading researchers including Lorenz Studer at MSKCC for stem cell and neurodegenerative disease research, Tuomas Tammela for cancer genomics, and multiple immunology researchers studying T cell function in autoimmunity and cancer. His work bridges computational methodology development with direct biomedical applications across multiple disease areas.
Andrew McArthur is a Professor in the Department of Biochemistry & Biomedical Sciences at McMaster University, where he leads the McArthur Laboratory. His research focuses on bioinformatics , genomics , and computational biology with a specialization in genomic surveillance of antimicrobial resistance (AMR) . He spearheads the Comprehensive Antibiotic Resistance Database (CARD) and collaborates with the Canadian Anti-Infective Innovation Network (CAIN) , GenEpio Consortium , and IRIDA Platform for pathogen genomics. Education : PhD in Biochemistry (University of Victoria, 1996), Postdoctoral work at Marine Biological Laboratory (1998-1999) and National Museum of Natural History (1996-1998) His research spans antimicrobial resistance surveillance , machine learning applications , viral genomics (including SARS-CoV-2), and pathogen evolution . He has developed tools like CARD and IRIDA to standardize AMR data and enable rapid infectious disease analysis. Recent work includes machine learning models for predicting AMR, cloud-based pathogen detection , and resistome profiling in clinical and environmental contexts. He has mentored graduate students including Jalees Nasir (HSGSA Impact Award 2025), Dirk Hackenberger , Autumn Arnold , and Emily Bordeleau , as well as postdoctoral fellows like Sheridan Baker . His teaching includes courses in practical bioinformatics and biomedical consulting at McMaster University.
Massachusetts Institute of TechnologyUnited States
Jonathan Weissman is a Professor of Biology at the Massachusetts Institute of Technology (MIT) and a Member of the Whitehead Institute. He is also an Investigator of the Howard Hughes Medical Institute and the Landon T. Clay Professor of Biology. His research spans protein folding mechanisms, ribosome profiling, CRISPR-based tools (CRISPRi/a), and genetic interaction mapping. Whitehead Institute Member MIT Professor HHMI Investigator Co-founder, Maze Therapeutics & KSQ Therapeutics Research Interests focus on: Protein folding in cellular contexts Endoplasmic reticulum (ER) function and stress responses Genome-wide CRISPR screening for gene regulation High-density genetic interaction maps in mammals Mitochondrial protein targeting and quality control Epigenomic engineering with synthetic tools Scientific Awards include: Protein Society Irving Sigal Young Investigator Award (2004) Raymond & Beverly Sackler Prize (2008) National Academy of Sciences election (2009) NAS Award for Scientific Discovery (2015) Genetics Society of America Ira Herskowitz Award (2020) Labs & Collaborations : Leads the Weissman Lab at MIT/Whitehead Institute, co-leads the Laboratory for Genomic Research with GlaxoSmithKline, and chairs the Stowers Institute Scientific Advisory Board.
Ryan B. Jensen is an Associate Professor of Therapeutic Radiology and Pathology at Yale School of Medicine. His research is primarily focused on DNA repair mechanisms, with a special emphasis on the BRCA2 protein and homologous recombination pathways. He directs the Jensen Lab, which is affiliated with multiple Yale research centers including the Yale Cancer Center, Women's Health Research at Yale, and the Yale Combined Program in the Biological and Biomedical Sciences. Yale School of Medicine - Therapeutic Radiology Department (Primary Appointment) Yale School of Medicine - Pathology Department (Secondary Appointment) DNA Damage and Genome Integrity Research Group Molecular Medicine, Pharmacology, and Physiology Program WHRY Pilot Project Program Investigators Yale Ventures Dr. Jensen's research centers on understanding the molecular mechanisms of DNA double-strand break repair, particularly the role of BRCA2 in homologous recombination. His lab employs a multi-disciplinary approach combining biochemistry, genetics, cell biology, structural biology, and proteomics to investigate how BRCA2 and other proteins involved in homologous recombination signal and catalyze DNA repair reactions. A major focus is on understanding the functional consequences of BRCA2 interactions with proteins like PALB2, BRCA1, FANCD2, EMSY, DMC1, and DSS1, and how disruptions in these pathways lead to cancer development. Analysis of Dr. Jensen's recent publications (2019-2025) reveals a consistent research trajectory focused on BRCA2 function, DNA repair mechanisms, and cancer biology. His work spans fundamental biochemical characterization of DNA repair proteins, development of novel methodologies for studying replication dynamics, and translational research connecting DNA repair defects to cancer therapeutics. A notable trend is the increasing focus on clinical applications, particularly regarding BRCA2 variants of uncertain significance and their implications for personalized cancer treatment. Dr. Jensen has collaborated extensively with researchers across Yale, with frequent co-authors including Peter M. Glazer, Ranjit S. Bindra, Adam Krysztofiak, Faye Rogers, Fengshan Liang, and Joann Sweasy. His work has appeared in high-impact journals including Nature, Molecular Cell, and ELife. As a mentor, Dr. Jensen oversees graduate and undergraduate students in his lab, including Jennifer Garbarino and Joshua Matthew. His research has been supported by various funding mechanisms that enable the multi-disciplinary approach to studying DNA repair mechanisms and their implications for cancer biology and treatment. Dr. Jensen leads the Jensen Lab, which maintains a strong focus on understanding the molecular basis of DNA repair and its connection to cancer development. The lab has developed specialized techniques for purifying and characterizing large DNA repair proteins like BRCA2, which has enabled groundbreaking biochemical studies of these critical cancer-related proteins.
Alejandro Benjamin Balazs is an Assistant Professor of Medicine at the Ragon Institute of MGH, MIT, and Harvard. His laboratory specializes in synthetic immunology, gene transfer technologies, and immune system engineering to combat HIV and emerging viral threats like SARS-CoV-2. Current research focuses include: Understanding sterilizing immunity mechanisms against HIV. Studying pathogen escape from immunological pressure. Optimizing AAV vector delivery for broadly neutralizing antibodies. Investigating innate immune responses in viral neutralization. His lab has published extensively on: Antibody-mediated prophylaxis against HIV and SARS-CoV-2. Viral evolution and immune escape dynamics. AAV-based gene delivery systems. Humoral immunity in vulnerable populations. Immune signatures in humanized mouse models. Scientific accolades include: NIDA Avenir New Innovator (DP2) Grant (2015) Gilead Sciences Research Scholars Award (2016) MGH Transformative Research Scholars Award (2016) Doctoral students mentored in his lab include: Jackie Brady (Harvard BBS Program, 2015-2020) Allen Lin (Harvard Systems Biology, 2015-2020) Meredith Phelps (Harvard Virology, 2018-2022)
Assistant Professor Low Jun Siong is affiliated with the Department of Microbiology and Immunology at the National University of Singapore (NUS), under the Yong Loo Lin School of Medicine. His research focuses on understanding T and B cell biology in the context of infection, cancer, and autoimmunity. He collaborates with clinical partners to characterize immune cell responses in patient cohorts and explores strategies to manipulate these cells for therapeutic purposes. Key areas of interest include antigen specificity, immune cell dysfunction, and immune-based disease interventions. Education: Holds a BSc and PhD (specific disciplines unspecified). Affiliated with the Cancer Science Institute (CSI) and A*STAR Infectious Diseases Labs. His work spans translational immunology, virology, and cancer immunotherapy. Recent projects include studies on SARS-CoV-2 immune responses, tumor microenvironment interactions, and tropical sponge microbiome evolution. He employs high-throughput approaches and machine learning for immune profiling. Research highlights include: Characterizing T/B cell responses against pathogens and cancers Engineering immune cells for enhanced functionality Investigating antibody mechanisms against coronaviruses Dissecting metabolic influences on T cell efficacy in tumors Exploring symbiotic microbiome evolution in marine environments No specific grants or advising roles are detailed in the provided text. He contributes to collaborative initiatives like the Department Safety and Health Programme (DSHP) and the Department Microbial Culture Collection (DMCC).
Associate Professor Justin Chu Jang Hann is affiliated with the Department of Microbiology and Immunology at the National University of Singapore (NUS), within the Yong Loo Lin School of Medicine. He holds additional roles as Assistant Dean (Academic Affairs) in the School of Medicine, Director of the NUS Medicine BSL-3 & ABSL-3 Core Facility, and Joint Senior Principal Investigator at the Institute of Molecular and Cell Biology (IMCB) A*STAR. His research focuses on molecular RNA virology, antiviral strategies, and high-throughput imaging technologies to study host-pathogen interactions. Key projects include genomic screening of viral-host interactions, high-content bio-imaging platforms, and development of anti-viral compounds against pathogens like SARS-CoV-2, dengue, and enteroviruses. Recent work explores broad-spectrum antivirals, vaccine candidates, and diagnostic approaches for viral infections. His contributions span virology, immunology, and translational medicine, with a strong emphasis on combating emerging and re-emerging RNA viruses.
